Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

NCT03994627 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Olaratumab

Sponsor

Eli Lilly and Company